Neoplasm Metastasis
313
15
27
185
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
54 trials with published results (17%)
Research Maturity
185 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
39 terminated out of 313 trials
82.6%
-4.0% vs benchmark
14%
44 trials in Phase 3/4
29%
54 of 185 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 185 completed trials
Clinical Trials (313)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors
A Study of LY4175408 in Participants With Advanced Cancer
Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
CIRSE Emprint Microwave Ablation Registry